Skip to main content
. 2017 Oct 27;8(63):106948–106961. doi: 10.18632/oncotarget.22157

Figure 4. Results of meta-analysis for TET2.

Figure 4

Combined response rate for patients with TET2 mutated (response rate: 56%; 95%CI: 42–69%) resulted significantly higher than that of the remaining patients with TET2 wild-type (RR: 43%; 95%CI: 35–52%). The pooled odds ratio of response was favourable to TET2 mutations (pooled OR=1.67, 95%CI: 1.14–2.44, p=0.01). Abbreviations: OR, odds ratio: RR, response rate; WT, wild-type.